Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina

Roche logo

Roche

Status

Completed

Conditions

Chronic Lymphocytic Leukemia

Treatments

Biological: Obinutuzumab

Study type

Observational

Funder types

Industry

Identifiers

NCT03059251
ML30187

Details and patient eligibility

About

This observational study aims to study the effectiveness and safety of Obinutuzumab in common clinical practice settings in Argentina. The study population comprises all patients with chronic lymphocytic leukemia (CLL) that have received the indication for treatment with Obinutuzumab as per routine clinical practice.

Enrollment

2 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Have received at least one dose of Obinutuzumab as per local label and clinical practice.

Exclusion criteria

Included in clinical trial

Trial design

2 participants in 1 patient group

Obinutuzumab
Description:
All participants with chronic lymphocytic leukemia (CLL) who have received the indication for treatment with Obinutuzumab, as per routine clinical practice in Argentina.
Treatment:
Biological: Obinutuzumab

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems